13F Holdings
中文EN

BLTE BELITE BIO, INC Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1889109 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-114.7%
TTM EPS YoY-95.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-16.9%
ROA-16.6%
ROIC (approx.)-25.0%
Asset turnover—

Leverage & solvency

Liabilities / assets1.3%
Debt / equity0.00x
Current ratio50.02x
Interest coverage-42,104.00x

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio-8.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$45.38M$29.94M$24.84M$8.87M$7.42M
SG&A expense$38.83M$10.06M$6.82M$3.95M$2.38M
Operating income-$84.21M-$40.00M-$31.67M-$12.82M-$9.80M
Interest expense$2,000$20,000$25,000$16,000—
Pretax income-$77.61M-$36.14M-$31.62M-$12.65M-$9.67M
Income tax$0$6,000$9,000——
Net income-$77.61M-$36.14M-$31.63M-$12.65M-$9.67M
EBITDA-$84.04M-$39.83M-$31.53M-$12.76M-$9.77M
EPS (basic)-2.31-1.18-1.19-0.63-1.01
EPS (diluted)-2.31-1.18-1.19-0.63-1.01
Weighted avg. shares (diluted)33.54M30.54M26.59M19.98M9.57M
Balance sheet
Cash & equivalents$352.93M$31.68M$88.16M$42.09M$17.34M
Short-term investments—$4.55M———
Current assets$494.27M$147.07M$89.94M$42.81M$17.43M
PP&E, net$344,000$444,000$490,000$541,000$94,000
Intangibles$19,000$31,000———
Total assets$780.56M$152.13M$94.64M$44.27M$18.35M
Current liabilities$9.88M$6.05M$3.63M$2.10M$1.64M
Total liabilities$10.07M$6.31M$4.21M$2.77M$1.64M
Shareholders' equity$770.49M$145.82M$90.43M$41.50M-$15.09M
Shares outstanding39.34M31.83M29.15M24.90M10.27M
Cash flow statement
Operating cash flow-$36.99M-$29.23M-$29.84M-$11.46M-$7.47M
Capital expenditure$71,000$116,000$63,000$394,000$74,000
Free cash flow-$37.06M-$29.35M-$29.90M-$11.85M-$7.55M
Investing cash flow-$305.11M-$110.57M-$63,000-$394,000-$56,000
Financing cash flow$663.23M$83.59M$75.96M$36.96M-$583,000
Depreciation & amortization$172,000$164,000$139,000$64,000$30,000
Stock-based compensation$38.92M$8.99M$3.82M$1.48M$1.53M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.